Larazotide is currently being studied for illnesses of intestinal permeability and is the subject of a late-phase clinical trial for patients with celiac disease, whose intestinal barrier is compromised
Topical/cosmetic GHK-Cu Human studies on GHK-Cu have primarily focused on the topical route of administration
After the study, it was observed that both the peptides appeared to have the potential to restore basic bodily functions in geriatric subjects including improved functions in the cardiovascular, endocrinal, immune, and nervous systems, along with normalized metabolic and hemostatic activities
ZR2024QH068) and the Research Fund for Lin Hes Academician Workstation for New Medicine and Clinical Translation at Jining Medical University (No
Versatile Dosage Options: Available in 100,000 IU for elderly and 200,000 IU for adults and adolescents